GlassScriptPhysician profile
Sarah Ellen Thomas
NPI 1841264058
$9,988.17
in general payments reported to CMS, 2019-2025
31 companies · $3,177 in 2025
The $3,177 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $695 · 2022: $2,516 · 2023: $2,071 · 2024: $1,529 · 2025: $3,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,776.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,094.50 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,206.09 | 2022-2025 | Dupixent |
| Csl Behring | $886.81 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $834.51 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $640.91 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $539.28 | 2021-2025 | |
| Pfizer INC. | $348.32 | 2022-2025 | |
| Abbvie INC. | $319.01 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $242.75 | 2025 | Neffy |
| Grifols USA, LLC | $223.79 | 2021-2024 | Xembify |
| Optinose US, INC. | $217.82 | 2022-2025 | |
| Amgen INC. | $189.92 | 2021-2023 | Tezspire |
| Pharming Healthcare, INC. | $171.62 | 2021-2024 | Ruconest |
| Galderma Laboratories, L.P. | $129.01 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.13 | 2021-2023 | Spiriva Respimat |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $103.40 | 2025 | Oralair |
| Blueprint Medicines Corporation | $90.88 | 2024-2025 | Ayvakit |
| Genentech USA, INC. | $89.34 | 2022-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $78.10 | 2025 | |
| Kaleo, INC. | $73.71 | 2021-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $65.73 | 2022-2023 | Airduo Digihaler |
| Ionis Pharmaceuticals, INC. | $60.67 | 2025 | Dawnzera |
| Insmed, INC. | $47.03 | 2025 | Brinsupri, Arikayce |
| Leo Pharma INC. | $36.87 | 2023 | Adbry |
| Biocryst US Sales Co., LLC | $34.20 | 2024 | Orladeyo |
| Aimmune Therapeutics, INC. | $28.17 | 2022 | |
| Teleflex LLC | $25.39 | 2024 | Guideliner |
| Incyte Corporation | $22.76 | 2021 | |
| Phadia US INC. | $21.70 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $20.55 | 2023 | |
| Gc Biopharma USA, INC. | $17.20 | 2025 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.